A Look At The COVID-19 Vaccine Stocks

Lab, Research, Laboratory, Chemistry, Scientist

Image Source: Pixabay

Based on data as of April 28 from the CDC, over 142 million Americans have received one dose of the COVID-19 vaccine and more than 90 million have been fully vaccinated. This amounts to about 68% of those over 65, 38% of those over 18, and approximately 30% of the U. S. population.

The big players in the coronavirus vaccine arena are Pfizer (PFE), which is in partnership with BioNTech (BNTX), Moderna (MRNA), Johnson & Johnson (JNJ), and AstraZeneca (AZN). Of course, there are a lot of smaller biotech companies involved in COVID-19 testing, treatment, and cures.

The first vaccine, a two-dose variety, was created by the Pfizer and BioNTech joint venture. Pfizer, with a market cap of $215 billion, trades at 22.6 times trailing earnings and 12 times forward earnings. It pays a generous yield of 4.04%. The company raised its dividend by 2.6% in January of this year, and has raised its dividend every year for over ten years.

BioNTech is a German-based biotechnology company with a market cap of $46 billion. Trailing earnings have been negative, but the forward price to earnings ratio is 19.7. The stock does not pay a dividend. Moderna was close on their heels with its own two-dose vaccine. This $70 billion company has a forward P/E ratio of 8.7 and has no dividends.

Johnson & Johnson subsequently released a one-dose vaccine, however, health issues were raised about the vaccine relating to blood clots affecting a very small number of people, plus there was a contamination issue relating to blood clots. J&J trades at 29 times trailing earnings and 17 times forward earnings. The dividend yield is a healthy 2.62%. The company recently announced a 4.95% increase in the dividend payout beginning in June.

Finally, the British company AstraZeneca has a vaccine, but it is not yet approved by the U.S. Food and Drug Administration. So far, its vaccine has brought in $275 million in sales. The company has a market cap of $135 billion, a trailing P/E ratio of 42 and a forward P/E ratio of 21. The forward annual dividend yield is 2.7%. The dividend is paid semi-annually. Maybe one of these stocks can not only protect you, but also your portfolio.

Disclosure: Author owns PFE.

Disclaimer: This article is designed to provide information. It is provided with the understanding that neither the author nor the publisher is ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.